Fig. 7: Ent treatment arrests tumor progression and provides therapeutic benefits in PDAC GEMM.
From: Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
a, b Representative tumor images (a) and tumor weight measurement (b) from GEMM (KPf/fC mice) after 3-week treatment of Veh, Ent (5 mg/kg, daily), Gem (25 mg/kg, q3d) or the combination of Ent and Gem. Scale bar, 10 mm. n = 7 (Veh, Ent, Ent+Gem), 4 (Gem) mice. c Kaplan-Meier curves showing the survival time after treatment initiation in KPf/fC mice. n = 15 (Veh), 16 (Ent), 11 (Gem), 18 (Ent+Gem) mice. Median survival (d): 22 (Veh), 29 (Ent), 28 (Gem), 34.5 (Ent+Gem). d, e Pathological grading of tumor samples from Veh- or Ent-treated KPf/fC at moribund (d), and representative images of Grades 2 (well differentiated) and 4 (poorly differentiated) tumor sections with hematoxylin and eosin (H&E) staining (e). Scale bar, 25 μm. n = 10 tumors. f, g Measurements of total CK19, α-SMA, and Ki67 and SR positive areas (f) and ratio of CK19+ over α-SMA+ areas (g) in the whole tumor sections from KPf/fC mice under Veh or Ent treatment. n = 10 (f, CK19+), 8 (Veh in f, α-SMA+ and g), 7 (Ent in f, α-SMA+ and g), 6 (f, SR+ and Ki67+). p = 0.904 (g). Data in b, f, g are presented as mean values ± SEM. *p < 0.05, =0.025 (b, Ent+Gem vs Ent), 0.019 (b, Ent+Gem vs Gem), 0.013 (f, α-SMA+), 0.029 (f, SR+); **p < 0.01, =0.002 (c, Gem vs Ent+Gem), 0.004 (f, CK19+), 0.001 (f, Ki67+); ***p < 0.001 (b, Ent vs Veh; c, Ent vs Veh; c, Ent+Gem vs Ent). Survival analysis (c), log-rank test; others (b, f), two-sided t-test. Source data are provided as a Source Data file.
